{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:05:41Z","timestamp":1771437941746,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15482-1","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:49:18Z","timestamp":1768898958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+\/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study"],"prefix":"10.1186","volume":"26","author":[{"given":"Marina Elena","family":"Cazzaniga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Fulvia","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Cogliati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Sandretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Capici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"3","key":"15482_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung H. \"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries\". CA Cancer J Clin. 2021;71(3):209\u2013249. https:\/\/doi.org\/10.3322\/CAAC.21660.","journal-title":"CA Cancer J Clin"},{"key":"15482_CR2","unstructured":"Cos\u2019\u00e8 il Cancro | AIRC., Accessed. Apr. 04, 2025. Available: https:\/\/www.airc.it\/cancro\/informazioni-tumori\/cose-il-cancro\/numeri-del-cancro."},{"issue":"9","key":"15482_CR3","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/PNAS.191367098","volume":"98","author":"T S\u00f8rlie","year":"2001","unstructured":"S\u00f8rlie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(9):10869\u201374. https:\/\/doi.org\/10.1073\/PNAS.191367098.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"15482_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMOA2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN, et al. \"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer\". N Engl J Med. 2022;386(10):942\u201350. https:\/\/doi.org\/10.1056\/NEJMOA2114663.","journal-title":"N Engl J Med"},{"issue":"20","key":"15482_CR5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMOA1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMOA1607303\/SUPPL_FILE\/NEJMOA1607303_DISCLOSURES.PDF.","journal-title":"N Engl J Med"},{"issue":"8","key":"15482_CR6","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/J.ANNONC.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35(8):718\u201327. https:\/\/doi.org\/10.1016\/J.ANNONC.2024.04.013.","journal-title":"Ann Oncol"},{"key":"15482_CR7","doi-asserted-by":"publisher","unstructured":"Bidard F-C et al. Elacestrant (oral selective Estrogen receptor degrader) versus standard endocrine therapy for Estrogen receptor-Positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;32. https:\/\/doi.org\/10.1200\/JCO.22.00338.","DOI":"10.1200\/JCO.22.00338"},{"key":"15482_CR8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer 5 behalf of the ESMO guidelines committee. Ann Oncol. 2021;32:1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019.","journal-title":"Ann Oncol"},{"key":"15482_CR9","unstructured":"Types of chemotherapy. MedlinePlus Medical Encyclopedia. Accessed: May 25, 2025. Available: https:\/\/medlineplus.gov\/ency\/patientinstructions\/000910.htm."},{"issue":"8","key":"15482_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045\u20137. https:\/\/doi.org\/10.1172\/JCI9872.","journal-title":"J Clin Invest"},{"key":"15482_CR11","doi-asserted-by":"publisher","unstructured":"Cazzaniga ME, et al. Metronomic chemotherapy with oral Vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Res Treat. 2016;160(3). https:\/\/doi.org\/10.1007\/s10549-016-4009-3.","DOI":"10.1007\/s10549-016-4009-3"},{"key":"15482_CR12","doi-asserted-by":"publisher","unstructured":"Cazzaniga ME, et al. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: final results of the VICTOR-6 study. Breast. 2019;48. https:\/\/doi.org\/10.1016\/j.breast.2019.07.006.","DOI":"10.1016\/j.breast.2019.07.006"},{"issue":"9","key":"15482_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/JAMAONCOL.2023.2150","volume":"9","author":"E Munzone","year":"2023","unstructured":"Munzone E, et al. Sep., Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. JAMA Oncol. 2023;9(9):1267\u201372. https:\/\/doi.org\/10.1001\/JAMAONCOL.2023.2150.","journal-title":"JAMA Oncol"},{"key":"15482_CR14","doi-asserted-by":"publisher","unstructured":"Montagna E, et al. The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. Anticancer Drugs. 2022;33(1). https:\/\/doi.org\/10.1097\/CAD.0000000000001209.","DOI":"10.1097\/CAD.0000000000001209"},{"issue":"6","key":"15482_CR15","doi-asserted-by":"publisher","first-page":"pkad074074","DOI":"10.1093\/JNCICS\/PKAD074","volume":"7","author":"R Amorrortu","year":"2023","unstructured":"Amorrortu R, et al. Overview of approaches to estimate real-world disease progression in lung cancer. JNCI Cancer Spectr. 2023;7(6):pkad074074. https:\/\/doi.org\/10.1093\/JNCICS\/PKAD074.","journal-title":"JNCI Cancer Spectr"},{"issue":"12","key":"15482_CR16","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/J.ANNONC.2023.10.001\/ATTACHMENT\/1DE7E9A7-7499-484F-A53B-2901B1714FBA\/MMC1.DOCX","volume":"34","author":"L Castelo-Branco","year":"2023","unstructured":"Castelo-Branco L, et al. ESMO guidance for reporting oncology real-World evidence (GROW). Ann Oncol Dec. 2023;34(12):1097\u2013112. https:\/\/doi.org\/10.1016\/J.ANNONC.2023.10.001\/ATTACHMENT\/1DE7E9A7-7499-484F-A53B-2901B1714FBA\/MMC1.DOCX.","journal-title":"Ann Oncol Dec"},{"issue":"1","key":"15482_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-13-16\/TABLES\/4","volume":"13","author":"S Galimberti","year":"2013","unstructured":"Galimberti S, Valsecchi MG. Multivariate permutation test to compare survival curves for matched data. BMC Med Res Methodol. 2013;13(1):1\u201310. https:\/\/doi.org\/10.1186\/1471-2288-13-16\/TABLES\/4.","journal-title":"BMC Med Res Methodol"},{"key":"15482_CR18","doi-asserted-by":"publisher","unstructured":"Trevisan B, et al. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients. Sci Rep. 2023;13(1). https:\/\/doi.org\/10.1038\/s41598-023-39386-x.","DOI":"10.1038\/s41598-023-39386-x"},{"issue":"9","key":"15482_CR19","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/SJ.BJC.6600261","volume":"86","author":"DC Talbot","year":"2002","unstructured":"Talbot DC, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda\u00ae) with Paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines. Br J Cancer. 2002;86(9):1367. https:\/\/doi.org\/10.1038\/SJ.BJC.6600261.","journal-title":"Br J Cancer"},{"issue":"34","key":"15482_CR20","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","volume":"29","author":"MR Stockler","year":"2011","unstructured":"Stockler MR, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 2011;29(34):4498\u2013504. https:\/\/doi.org\/10.1200\/JCO.2010.33.9101.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15482_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1634\/THEONCOLOGIST.2011-0281","volume":"17","author":"JA O\u2019Shaughnessy","year":"2012","unstructured":"O\u2019Shaughnessy JA, et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist Apr. 2012;17(4):476\u201384. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2011-0281.","journal-title":"Oncologist Apr"},{"key":"15482_CR22","doi-asserted-by":"publisher","unstructured":"Freyer G, et al. Single-agent metronomic versus weekly oral Vinorelbine as first-line chemotherapy in patients with HR-positive\/HER2-negative advanced breast cancer: the randomized tempo breast study. Breast. 2024;74. https:\/\/doi.org\/10.1016\/j.breast.2024.103681.","DOI":"10.1016\/j.breast.2024.103681"},{"key":"15482_CR23","doi-asserted-by":"publisher","unstructured":"Battaiotto E, d\u2019Ambrosio S, Trapani D, Curigliano G. Metronomic chemotherapy in breast cancer as a strategy to deliver more sustainable and less toxic treatments: time to debunk the myth? Clin Breast Cancer. 2025;25(2). https:\/\/doi.org\/10.1016\/J.CLBC.2024.11.003.","DOI":"10.1016\/J.CLBC.2024.11.003"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15482-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15482-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15482-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:07:30Z","timestamp":1771434450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15482-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15482"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15482-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Comitato Etico Regionale Lombardia 3 on March 12, 2025. Informed consent was obtained from all alive subjects involved in the study. For those who died, or could not be located, consent was not required, in accordance with the General Authorization to Process Personal data for Scientific Research Purposes (1 March 2012) issued by the Guarantor for the protection of Personal data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"245"}}